Industry News — Clinical Updates

Preclinical Data Demonstrate Sustained Release of Bevacizumab Using Tethadur

pSivida Corp. (Watertown, Mass.) has announced that preclinical studies show long-term sustained release of antibodies such as bevacizumab is achievable with Tethadur, a form of pSivida's BioSilicon technology.

The study evaluated the effect of pore size in Tethadur on bevacizumab release over a 3-week period and demonstrated that the release of antibodies was controllable over a wide range by adjusting pore size and surface area of Tethadur

According to pSivida, the ability to control the duration of sustained delivery of antibodies through pore size is significant. By varying the pore size, which controls the release rate of antibodies loaded into Tethadur, sustained delivery of antibodies such as bevacizumab could be permitted.

Tethadur is a platform drug delivery system that relies on nanostructuring to provide sustained delivery of large biologic molecules, including peptides, proteins, and antibodies. BioSilicon technology utilizes a fully erodible, honeycomb structure of nanoporous, elemental silicon to provide sustained delivery of therapeutics.

The findings were presented during the 2014 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.

Updated May 6, 2014